Biogen Inc (BIIB) dropped 8.21% after new clinical results and an FDA approval on Alzheimer's programs highlighted increased volatility in trading. The move is supported by the stock's failure to ...
Biogen Inc. (BIIB) stock is trading at $193.75, marking a sharp decline of 7.31% on the day. The price currently sits below its key short- and medium-term moving ...
Biogen Inc. (BIIB) stock is trading at $194.83, down 1.94% on the day and closing near its intraday low. The recent decline places the share price below its key short- ...